Invictus Appoints Music Legend &
Media Mogul Gene Simmons as Chief Evangelist
Officer
Vancouver, BC -- March 14,
2018 -- InvestorsHub NewsWire -- INVICTUS MD STRATEGIES
CORP. ("Invictus" or the "Company") (TSXV:
IMH;
OTC: IVITF; FRA: 8IS1) announced today that rock ’n’ roll legend
and marketing and branding innovator Gene Simmons,
co-founder of KISS: America’s #1 Gold Record Award Winning
Group of all time, has joined Invictus as Chief Evangelist
Officer.
The partnership involves
Simmons' leadership in a variety of capacities focused on assisting
the Company with its public awareness strategy and eventual
branding strategy for the recreational market that is anticipated
to be legal in Canada in 2018. His responsibilities will
include providing marketing counsel, serving as a spokesperson in
the media, public appearances and participation in the Company’s
annual general meeting and investor meetings, among
others.
“Gene Simmons is a
branding and merchandising genius, who not only created one of the
most iconic bands of all time, but has spent decades building
successful brands internationally in various industries,” said Dan
Kriznic, Chairman and CEO of Invictus. “Gene will lead marketing
initiatives that will help spread the positive messages that dwell
at the heart of Invictus in accordance with the strict regulations
of Health Canada's Access to Cannabis for Medical Purposes
Regulations (ACMPR), the Food and Drugs Act (FDA) and the Narcotic
Control Regulations (NCR)" said Kriznic.
“Values and family are very
important to me, and when I first connected with Dan at Invictus, I
understood immediately that we enjoyed a shared passion for these
key life foundations,” said Gene. “Instead of launching straight
into business, we talked about the things that matter the
most.”
While Simmons has achieved
extraordinary success beyond the concert stage and recording
studio, his KISS-related achievements are astounding in themselves
with the band having sold more than 100 million albums; earning
more American Gold Record Awards than any other group, in all
categories (RIAA); building a merchandising/licensing empire with
over 2,500 licenses including everything from t-shirts and comic
books, to pinball machines, credit cards and lunchboxes; and
breaking box office records set by The Beatles and
Elvis.
Beyond KISS, Simmons’ celebrity
television show, Gene Simmons Family Jewels, aired for eight years
and 167 episodes, and was viewed in 84 countries — one of the
longest-running celebrity reality TV shows in history. He
discovered Van Halen, managed the recording career of Liza
Minnelli, and is a founding partner in the global restaurant chain
Rock & Brews.
Simmons’ achievements in
marketing encouraged McClaren to hire him as their brand ambassador
and Indycar engaged him to do their marketing. Simmons has a record
label Simmons Records, is a published author with Simmons Books
about to publish his latest book “27”, on the heels of his two
previous best sellers Me, Inc., and On Power; and Simmons Comics
continues to grow. In addition, he published his own magazine,
Tongue (Sterling-McFadden) and is about to launch his newest
magazine, “iMOGU” focusing on entrepreneurs that matter. Simmons
created and executive produced the TV shows My Dad The Rock Star,
Mr. Romance, and others. He has also acted in numerous motion
pictures and television shows for more than three decades and is
currently co-producing a slate of motion pictures with Arclight
Films.
Simmons is a partner in
the New York-based Family Office of Highmore Group Advisors,
he has rang the bell at the New York Stock Exchange and the
Toronto Stock Exchange, and was keynote speaker at NASDAQ.
Gene Simmons also had a United States Postage
Stamp.
Among his latest ventures,
Simmons is launching a premium soda line, MoneyBag™ Sodas, across
all 7-Eleven stores; his 50th anniversary rock tour, Gene Simmons:
The Vault Experience, continues with stops around the world; and,
he will soon launch MoneyBag™ FootGear.
Terms of the
agreement
Pursuant to the terms of the
agreement Invictus acquired all the issued and outstanding shares
of Gene-Etics Strains Co. from Gene Simmons and Simmons will
provide the marketing and branding efforts described above for
a purchase price comprising of $2.5-million (U.S.) payable in cash
and the issuance of 2,631,141 common shares in the capital of
Invictus to be paid on the closing date. Invictus and Simmons
will also enter into a management services agreement and
international licensing agreement, for an additional 1,973,355
common shares and a second tranche of 1,973,355 common shares to be
issued to Simmons on the later of 240 days following the closing
date and January 2, 2019.
The shares are being issued at
a deemed price of $1.97
About Invictus MD Strategies Corp.
Invictus MD Strategies Corp. is focused on two main verticals
within the Canadian cannabis sector, namely the Licensed
Producers under the ACMPR, being its 100% investment in Acreage
Pharms Ltd., located in West-Central Alberta, and 50% investment in
AB Laboratories Inc., located near Hamilton, Ontario, that has its
cultivation and sales license under ACMPR. In addition to ACMPR
licenses, the Company has an 82.5% investment in Future Harvest
Development Ltd. a Fertilizer and Nutrients manufacturer based
in Kelowna, British Columbia.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676
In the United States
Terry Wills
310-877-1458
Cautionary Note Regarding
Forward-Looking Statements: This release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian securities
laws or forward-looking statements within the meaning of the United
States Private Securities Litigation Reform Act of 1995. All
statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, timing, assumptions or expectations of future
performance, including Invictus’ successful negotiation and signing
of the international licensing agreement and the management
services agreement with Gene, the issuance of the second and third
tranche of the Company’s common shares to Gene and the legalization
of the recreational use of marijuana in Canada in 2018 are
forward-looking statements and contain forward-looking information.
Generally, forward-looking statements and information can be
identified by the use of forward-looking terminology such as
“intends” or “anticipates”, or variations of such words and phrases
or statements that certain actions, events or results “may”,
“could”, “should”, “would” or “occur”. Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including Invictus’ successful negotiation
and signing of the international licensing agreement and the
management services agreement with Gene, the issuance of the second
and third tranche of the Company’s common shares to Gene and the
legalization of recreational use of cannabis in Canada will occur
in 2018. These forward-looking statements are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information. Important factors that may cause
actual results to vary, include, without limitation, Invictus will
not successfully negotiate and sign the international licensing
agreement and the management services agreement with Gene, Invictus
will not issue the second and third tranche of the Company’s common
shares to Gene and the legalization of the recreational use of
marijuana in Canada will not occur at all or as expected.
Although management of the Company has attempted to identify
important factors that could cause actual results to differ
materially from those contained in forward-looking statements or
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can
be no assurance that such statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements and
forward-looking information. Readers are cautioned that reliance on
such information may not be appropriate for other purposes. The
Company does not undertake to update any forward-looking statement,
forward-looking information or financial out-look that are
incorporated by reference herein, except in accordance with
applicable securities laws. We seek safe harbor.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024